Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: Inclusion of quality of life and other patient-reported outcomes

Critical Reviews in Oncology/Hematology

Volumn 81, Issue 2, 2012, Pages 123-135

  Efficace, F ^a   Cocks, K ^b   Breccia, M ^c   Sprangers, M ^d   Meyers, C A ^e   Vignetti, M ^c   Baccarani, M ^f   Mandelli, F ^a  

^a Italian Group for Adult Hematologic Diseases (GIMEMA)   (Italy)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e UNIVERSITY OF TEXAS   (United States)

^f UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Chronic myeloid leukemia; Patient reported outcomes; Quality of life; Systematic review

Indexed keywords

ALPHA INTERFERON; BUSULFAN; HYDROXYUREA; IMATINIB; INTERFERON;

BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL EVALUATION; COGNITIVE DEFECT; DEPRESSION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DYSPNEA; FATIGUE; FLU LIKE SYNDROME; HUMAN; IRRITABILITY; LOW DRUG DOSE; MOOD DISORDER; MOTOR DYSFUNCTION; NAUSEA AND VOMITING; NEUROTOXICITY; PAIN; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL RATING SCALE; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SCORING SYSTEM; SELF REPORT; SIDE EFFECT; SKIN DISEASE; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

BONE MARROW TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULAR TARGETED THERAPY; QUALITY OF LIFE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84856211740     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.02.007     Document Type: Review

References (78)

1. Hehlmann R., Hochhaus A., Baccarani M. Chronic myeloid leukaemia. Lancet 2007, 370:342-350. on behalf of the European LeukemiaNet.
2. Deininger M. Chronic myeloid leukaemia: an historical perspective. Hematology Am Soc Hematol Educ Program 2008, 418.
3. Pavlovsky C., Kantarjian H., Cortes J.E. First-line therapy for chronic myeloid leukaemia: past, present and future. Am J Hematol 2009, 84:287-293.
4. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
5. Deininger M., O'Brien S.G., Guilhot F., et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood (ASH Annual Meeting Abstracts) 2009, 114. [abstract 1462].
6. Saglio G., Kim D.W., Issaragrisil S., et al. ENESTnd Investigators Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010, 362(June (24)):2251-2259.
7. Baccarani M., Cortes J., Pane F., et al. Chronic myeloid leukaemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009, 27:6041-6051.
8. Baccarani M., Saglio G., Goldman J., et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006, 108(September (6)):1809-1820.
9. Dalziel K., Round A., Stein K., et al. Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukemia in chronic phase: a systematic review and economic analysis. Health Technol Assess 2004, 8(28). iii1-120.
10. Osoba D. Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol 1994, 12:608-616.
11. Osoba D., Tannock I.F., Ernst D.S., et al. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 1999, 17:1654-1663.
12. Molica S. Quality of life in chronic lymphocytic leukemia: a neglected issue. Leuk Lymphoma 2005, 46:1709-1714.
13. Efficace F., Kemmler G., Vignetti M., Mandelli F., Molica S., Holzner B. Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials - a systematic review to evaluate the added value in supporting clinical decision making. Eur J Cancer 2008, 44:1497-1506.
14. Redaelli A., Stephens J.M., Brandt S., Botteman M.F., Pashos C.L. Short- and long-term effects of acute myeloid leukemia on patient health-related quality of life. Cancer Treat Rev 2004, 30:103-117.
15. ASCO Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology. J Clin Oncol 1996, 14:671-679.
16. National Cancer Institute: The NCI Strategic Plan for Leading the Nation. To eliminate the suffering and death due to cancer. National Institutes of Health Publication No. 06-5773. http://strategicplan.nci.nih.gov/pdf/nci_2007_strategic_plan.pdf.
17. US Food and Drug Administration Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims December 2009, U.S. Department of Health and Human Services Food and Drug Administration. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf.
18. Bottomley A., Therasse P. Quality of life in patients undergoing systemic therapy for advanced breast cancer. Lancet Oncol 2002, 3:620-628.
19. Bottomley A., Efficace F., Thomas R., Vanvoorden V., Ahmedzai S. Health-related quality of life in non small-cell lung cancer: methodologic issues in randomized controlled trials. J Clin Oncol 2003, 21:2982-2992.
20. Efficace F., Bottomley A., Vanvoorden V., Blazeby J.M. Methodological issues in assessing health-related quality of life of colorectal cancer patients in randomized controlled trials. Eur J Cancer 2004, 40:187-197.
21. Efficace F., Bottomley A., Van Andel G. Health-related quality of life in prostate carcinoma patients: a systematic review of randomized controlled trials. Cancer 2003, 97:377-388.
22. Efficace F., Novik A., Vignetti M., Mandelli F., Cleeland C.S. Health-related quality of life and symptom assessment in clinical research of patients with haematological malignancies: where are we now and where do we go from here?. Haematologica 2007, 92:1596-1598.
23. Efficace F., Bottomley A., Osoba D., et al. Beyond the development of health-related quality of life (HRQOL) measures. A checklist for evaluating HRQOL outcomes in cancer clinical trials-does HRQOL evaluation in prostate cancer research inform clinical decision-making?. J Clin Oncol 2003, 21:3502-3511.
24. Winters Z.E., Benson J.R., Pusic A.L. A systematic review of the clinical evidence to guide treatment recommendations in breast reconstruction based on patient-reported outcome measures and health-related quality of life. Ann Surg 2010, 252:929-942.
25. Blazeby J.M., Avery K., Sprangers M., Pikhart H., Fayers P., Donovan J. Health-related quality of life measurement in randomized clinical trials in surgical oncology. J Clin Oncol 2006, 24(July (19)):3178-3186.
26. Cocks K., King M.T., Velikova G., et al. Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials. Eur J Cancer 2008, 44:1793-1798.
27. Bottomley A., Coens C., Suciu S., et al. Adjuvant therapy with pegylated interferon Alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2009, 27(June (18)):2916-2923.
28. Taphoorn M.J., Stupp R., Coens C., et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol 2005, 6:937-944.
29. Van Meerbeeck J.P., Gaafar R., Manegold C., et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005, 23:6881-6889.
30. Bernhard J., Cella D.F., Coates A.S., et al. Missing quality of life data in cancer clinical trials: serious problems and challenges. Stat Med 1998, 17:517-532.
31. Fairclough D.L. Methods of anaysis for longitudinal studies of health-related quality of life. Quality of life assessment in clinical trials: methods and practice 1998, 227-247. Oxford University Press, Oxford, England. M.J. Staquet, R.D. Hays, P.M. Fayers (Eds.).
32. Osoba D., Rodrigues G., Myles J., Zee B., Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998, 16:139-144.
33. Pavol M.A., Meyers C.A., Rexer J.L., Valentine A.D., Mattis P.J., Talpaz M. Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology 1995, 45(May (5)):947-950.
34. Bertero C., Eriksson B.E., Ek A.C. A substantive theory of quality of life of adults with chronic leukaemia. Int J Nurs Stud 1997, 34(1):9-16.
35. Stalfelt A.M., Zettervall O. Quality of life in young patients with chronic myelocytic leukaemia during intensive treatment including interferon. Leuk Res 1997, 21(8):775-783.
36. Homewood J., Watson M., Richards S.M., Halsey J., Shepherd P.C. Treatment of CML using IFN-alpha: impact on quality of life. Hematol J 2003, 4(4):253-262.
37. Kluin-Nelemans H.C., Buck G., Le Cessie S., et al. Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups. Blood 2004, 103(12):4408-4415.
38. Scheibel R.S., Valentine A.D., O'Brien S., Meyers C.A. Cognitive dysfunction and depression during treatment with interferon-alpha and chemotherapy. J Neuropsychiatry Clin Neurosci 2004, 16(Spring (2)):185-191.
39. Molassiotis A., Morris P.J. The meaning of quality of life and the effects of unrelated donor bone marrow transplants for chronic myeloid leukemia in adult long-term survivors. Cancer Nurs 1998, 21(3):205-211.
40. Molassiotis A., Morris P.J. Quality of life in patients with chronic myeloid leukemia after unrelated donor bone marrow transplantation. Cancer Nurs 1999, 22(5):340-349.
41. Kiss T.L., Abdolell M., Jamal N., et al. Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation. J Clin Oncol 2002, 20(9):2334-2343.
42. Chang G., Orav E.J., Tong M.Y., Antin J.H. Predictors of 1-year survival assessed at the time of bone marrow transplantation. Psychosomatics 2004, 45(5):378-385.
43. Chang G., Orav E.J., McNamara T., Tong M.Y., Antin J.H. Depression, cigarette smoking, and hematopoietic stem cell transplantation outcome. Cancer 2004, 101(4):782-789.
44. Hayden P.J., Keogh F., Ni C.M., et al. A single-centre assessment of long-term quality-of-life status after sibling allogeneic stem cell transplantation for chronic myeloid leukaemia in first chronic phase. Bone Marrow Transplant 2004, 34(6):545-556.
45. Chang G., Orav E.J., McNamara T.K., Tong M.Y., Antin J.H. Psychosocial function after hematopoietic stem cell transplantation. Psychosomatics 2005, 46(1):34-40.
46. Hahn E.A., Glendenning G.A., Sorensen M.V., et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS study. J Clin Oncol 2003, 21(11):2138-2146.
47. Noens L., Van Lierde M.A., De Bock R., et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009, 113:5401-5411.
48. Aaronson N.K., Ahmedzai S., Bergman B., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365-376.
49. Derogatis L.R. The Psychosocial Adjustment to Illness Scale. J Psychosom Res 1986, 30:77-91.
50. Zigmond A.S., Snaith R.P. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983, 67:361-370.
51. Ware J.E., Sherbourne C.D. The MOS 36-item short form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992, 30:473-483.
52. Baker F., Curbow B., Wingard J.R. Development of the satisfaction with life domains scale for cancer. J Psychosoc Oncol 1992, 10:75-90.
53. Sutherland H.J., Fyles G.M., Adams G., et al. Quality of life following bone marrow transplantation: a comparison of patient reports with population norms. Bone Marrow Transplant 1997, 19:1129-1136.
54. Schipper H., Clinch J., McMurray A., Levitt M. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncology 1984, 2:472-483.
55. Beck A.T., Rush A.J., Shaw B.F., Emery G. Cognitive therapy of depression 1979, Guilford Press, New York.
56. Bacik J., Mazumdar M., Murphy B.A., et al. The functional assessment of cancer therapy-BRM (FACT-BRM) a new tool for the assessment of quality of life in patients treated with biologic response modifiers. Qual Life Res 2004, 13(February (1)):137-154.
57. The EuroQol Group EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990, 16:199-208.
58. Ware J.E., Kosinski M., Dewey J.E., Gandek B. How to score and interpret single-item health status measures: a manual for users of the SF-8 Health Survey 2001, QualityMetric Incorporated, Lincoln, RI.
59. Pidala J., Anasetti C., Jim H. Quality of life after allogeneic hematopoietic cell transplantation. Blood 2009, 114(July (1)):7-19.
60. Cortes J.E., Baccarani M., Guilhot F., et al. Phase III, randomized, open-label study of daily imatinib mesylate 400mg versus 800mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010, 28(January (3)):424-430.
61. Hehlmann R., Jung-Munkwitz S., Lauseker M., et al. Randomized comparison of imatinib 800mg vs imatinib 400mg±IFN in newly diagnosed BCR/ABL positive chronic phase CML: analysis of molecular remission at 12 months. Blood 2009, 114(Suppl.):143-144.
62. Baccarani M., Druker B.J., Cortes-Franco J., et al. 24 months update of the TOPS study: a phase III, randomized, open-label study of 400mg/d (SD-IM) versus 800mg/d (HD-IM) of imatinib mesylate (IM) in patients (Pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP). Blood (ASH Annual Meeting Abstracts) 2009, 114. [abstract 337].
63. Efficace F., Osoba D., Gotay C., Sprangers M., Coens C., Bottomley A. Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making. Ann Oncol 2007, 18:775-781.
64. Bottomley A., Flechtner H., Efficace F., et al. Health related quality of life outcomes in cancer clinical trials. Eur J Cancer 2005, 41(August (12)):1697-1709.
65. Sprangers M.A., Moinpour C.M., Moynihan T.J., et al. Assessing meaningful change in quality of life over time: a users' guide for clinicians. Mayo Clin Proc 2002, 77:561-571.
66. Revicki D., Hays R.D., Cella D., Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 2008, 61(2):102-109.
67. Williams L.A., Ault P., Wang S., et al. The symptom burden of chronic myelogenous leukemia (CML). Blood (ASH Annual Meeting Abstracts) 2008, 112. [abstract 2408].
68. Coons S.J., Gwaltney C.J., Hays R.D., et al. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report. Value Health 2009, 12(June (4)):419-429.
69. Chassany O., Sagnier P., Marquis P., et al. Patient-reported outcomes: the example of health related quality of life-a European guidance document for the improved integration of health related quality of life assessment in the drug regulatory process. Drug Inf J 2002, 36:209-238.
70. Staquet M., Berzon R., Osoba D., et al. Guidelines for reporting results of quality of life assessments in clinical trials. Qual Life Res 1996, 5:496-502.
71. Gotay C.C., Korn E.L., McCabe M.S., et al. Building quality of life assessment into cancer treatment studies. Oncology (Huntingt) 1992, 6:25-28.
72. Gotay C.C., Korn E.L., McCabe M.S., et al. Quality-of-life assessment in cancer treatment protocols: research issues in protocol development. J Natl Cancer Inst 1992, 84:575-579.
73. Fayers P.M., Hopwood P., Harvey A., et al. Quality of life assessment in clinical trials-guidelines and a checklist for protocol writers: the U.K. Medical Research Council experience, MRC Cancer Trials Office. Eur J Cancer 1997, 33:20-28.
74. Haes de J., Curran D., Young T., et al. Quality of life evaluation in oncological clinical trials - the EORTC model. Eur J Cancer 2000, 36:821-825.
75. Efficace F., Sprangers M. Designing and interpreting quality-of-life and other patient-reported outcomes in clinical trials. Education program for the 14th congress of the European Hematology Association (EHA) 2009, 89-95. Educational Book, Berlin, Germany.
76. Pinilla-Ibarz J., Cortes J., Mauro M.J. Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: definitions and clinical implications. Cancer 2011, 117:688-697.
77. Wang X.S., Cleeland C.S., Mendoza T.R., et al. Impact of cultural and linguistic factors on symptom reporting by patients with cancer. J Natl Cancer Inst 2010, 102(May (10)):732-738.
78. Pidala J., Anasetti C., Jim H. Health-related quality of life following haematopoietic cell transplantation: patient education, evaluation and intervention. Br J Haematol 2010, 148(February (3)):373-385.